文献速递特殊人群用药治疗药物监测与药物基因组学

基于生理药代动力学模型预测新生儿经胎盘获得恩曲他滨、多替拉韦和拉替拉韦的药代动力学

Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir.
PubMed 文献 · Clin Pharmacokinet · 2021-02-02

本研究开发并评估了一种基于生理药代动力学(PBPK)建模的工作流程,用于预测产前暴露于恩曲他滨、多替拉韦和拉替拉韦的新生儿在出生后即刻及最初数日的药代动力学。模型总体上捕捉了出生后的初始血浆浓度,但低估了终末相浓度;预测血浆浓度的平均百分比误差分别为-71.5%、-33.8%和76.7%。敏感性分析提示足月新生儿出生后最初数日有机阳离子转运体2和尿苷二磷酸葡萄糖醛酸转移酶1A1的活性分别约为成人的11%和30%。

要点

  • PBPK模型可预测经胎盘获得药物的新生儿洗脱浓度,但终末相预测欠佳。
  • 恩曲他滨、多替拉韦和拉替拉韦的预测平均百分比误差分别为-71.5%、-33.8%和76.7%。
  • 新生儿出生后初期OCT2和UGT1A1活性分别约为成人的11%和30%。

核心结论

  • 基于PBPK模型预测新生儿经胎盘获得药物洗脱浓度总体可行,可增进对出生后最初数日药代动力学的理解并预测药物暴露。

研究设计与样本

  • 利用已发表的恩曲他滨、多替拉韦和拉替拉韦母婴PBPK模型(PK-Sim/MoBi®)预测晚孕期胎盘药物转移,估算足月分娩时胎儿各隔室药物总量,并将其作为全身新生儿PBPK模型的初始条件,以预测出生后消除相药物浓度;新生儿消除过程根据已发表数据参数化,模型性能用临床数据评估。

主要发现

  • 新生儿PBPK模型总体上捕捉了分娩后的初始血浆浓度,但低估了终末相浓度。
  • 预测血浆浓度的平均百分比误差:恩曲他滨-71.5%,多替拉韦-33.8%,拉替拉韦76.7%。
  • 敏感性分析提示足月新生儿出生后最初数日OCT2活性约为成人的11%,UGT1A1活性约为成人的30%。

临床怎么用

  • 该PBPK建模工作流程可用于预测经胎盘获得药物在新生儿中的洗脱浓度,辅助理解出生后最初数日的药代动力学并预测药物暴露。

局限性

  • 模型低估了终末相药物浓度,预测性能存在偏差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Little is understood about neonatal pharmacokinetics immediately after delivery and during the first days of life following intrauterine exposure to maternal medications. Our objective was to develop and evaluate a novel, physiologically based pharmacokinetic modeling workflow for predicting perinatal and postnatal disposition of commonly used antiretroviral drugs administered prenatally to pregnant women living with human immunodeficiency virus. METHODS: Using previously published, maternal-fetal, physiologically based pharmacokinetic models for emtricitabine, dolutegravir, and raltegravir built with PK-Sim/MoBi®, placental drug transfer was predicted in late pregnancy. The total drug amount in fetal compartments at term delivery was estimated and subsequently integrated as initial conditions in different tissues of a whole-body, neonatal, physiologically based pharmacokinetic model to predict drug concentrations in the neonatal elimination phase after birth. Neonatal elimination processes were parameterized according to published data. Model performance was assessed by clinical data. RESULTS: Neonatal physiologically based pharmacokinetic models generally captured the initial plasma concentrations after delivery but underestimated concentrations in the terminal phase. The mean percentage error for predicted plasma concentrations was - 71.5%, - 33.8%, and 76.7% for emtricitabine, dolutegravir, and raltegravir, respectively. A sensitivity analysis suggested that the activity of organic cation transporter 2 and uridine diphosphate glucuronosyltransferase 1A1 during the first postnatal days in term newborns is ~11% and ~30% of that in adults, respectively. CONCLUSIONS: These findings demonstrate the general feasibility of applying physiologically based pharmacokinetic models to predict washout concentrations of transplacentally acquired drugs in newborns. These models can increase the understanding of pharmacokinetics during the first postnatal days and allow the prediction of drug exposure in this vulnerable population.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Liu XI, Momper JD, Rakhmanina NY, et al. Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. Clin Pharmacokinet. 2021. PMID: 33527213. doi:10.1007/s40262-020-00977-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。